drugset / Trial / NCT03940378
Treatment of Advanced Intrahepatic Cholangiocarcinoma
Phase 3
Unknown
152 enrolled
The First Affiliated Hospital of Zhengzhou University
Anyang Tumor Hospital · collabFirst Affiliated Hospital of Xinjiang Medical University · collabLuoyang Central Hospital · collabNanyang Central Hospital · collabSanmenxia Central Hospital · collabThird People's Hospital of Jiaozuo · collabpinmei Group General Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.
Timeline
- Start
- 2019-02-01
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levamisole | Small molecule | 150 mg | Oral |
| Background | Catequentinib | Small molecule | 12 mg | Oral |
Indications
No indication recorded.